Comparison of Effects of Different Heparins on Thrombin Activatable Fibrinolysis Inhibitor in Hemodialyzed Patients

Background: Thrombin activatable fibrinolysis inhibitor (TAFI) is a regulator of endogenous fibrinolysis. Heparin is used routinely during dialysis sessions to prevent clot formation in the extracorporeal circuit; therefore the aim of the study was to assess whether unfractionated heparin or low-molecular-weight heparins affect TAFI concentration and activity in hemodialyzed patients. Methods: Dalteparin (n = 16) or enoxaparin (n = 25) were administered before the second hemodialysis session in the week in a single dose, whereas unfractionated heparin (n = 18) was given first as a bolus, then in a pump. We also evaluated thrombin activity (thrombin-antithrombin complexes, prothrombin fragments 1 + 2), TAFI activator, thrombomodulin, a catalyzer of TAFI activation and a marker of endothelial cell injury, and the degree of plasmin generation (plasmin-antiplasmin complexes). Results: TAFI concentration, activity and markers of ongoing coagulation, i.e. prothrombin fragments 1 + 2 and thrombin-antithrombin complexes, were significantly higher in patients anticoagulated with unfractionated heparin when compared to both enoxaparin and dalteparin groups. Thrombin-antithrombin complexes, plasmin-antiplasmin complexes, prothrombin fragments 1 + 2, and thrombomodulin did not differ between patients anticoagulated with dalteparin and enoxaparin. Conclusions: Our results suggest that low-molecular-weight heparins influence TAFI and other hemostatic parameters in hemodialyzed patients to a lesser degree than unfractionated heparin. Increased TAFI is possibly due to thrombin appearance during hemodialysis with unfractionated heparin.

[1]  J. Małyszko,et al.  Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia. , 2003, Transplantation proceedings.

[2]  M. Myśliwiec,et al.  Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  M. Boffa,et al.  Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells* , 2003, The Journal of Biological Chemistry.

[4]  T. Lisman,et al.  Rebuttal to: Effect of heparin on TAFI‐dependent inhibition of fibrinolysis , 2003, Journal of thrombosis and haemostasis : JTH.

[5]  W. März,et al.  Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  G. La Manna,et al.  Standard Heparin versus Low-Molecular-Weight Heparin , 2002, Nephron.

[7]  N. Semeraro,et al.  Effect of Heparin on TAFI-Dependent Inhibition of Fibrinolysis: Relative Importance of TAFIa Generated by Clot-Bound and Fluid Phase Thrombin , 2002, Thrombosis and Haemostasis.

[8]  V. Kakkar,et al.  Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. , 2002, Blood.

[9]  J. Małyszko,et al.  Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of thrombin-activatable fibrinolysis inhibitor. , 2001, Thrombosis research.

[10]  B. Zinman,et al.  Association of a single nucleotide polymorphism in CPB2 encoding the thrombin‐activable fibrinolysis inhibitor (TAFI) with blood pressure , 2001 .

[11]  M. Myśliwiec,et al.  A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  A. Hartmann,et al.  Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  L. Bajzar.  Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[14]  F. Rosendaal,et al.  Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. , 2000, Blood.

[15]  J. Westhuyzen,et al.  Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  A. Hartmann,et al.  A single dose of dalteparin effectively prevents clotting during haemodialysis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  E. Ohman,et al.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. , 1998, Chest.

[18]  H. A. Ellis.  EFFECT OF HEPARIN , 2006 .

[19]  M. Halks-Miller,et al.  Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. , 2002, The Journal of clinical investigation.

[20]  A. Palazzuoli,et al.  Different mechanisms of fibrinolysis impairment among dyslipidemic subjects. , 2001, International journal of clinical pharmacology research.

[21]  E. Ohman,et al.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.